Clinical Trial Update: Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis [Phase 3]

View source ↗

Summary

Long-term Phase 3 trial assessing the safety and efficacy of Deucravacitinib for psoriasis; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING